Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 14 September 2021, 16:46 HKT/SGT
Share:
    

Source: Eisai
Eisai to Join The Global Environmental Initiative "RE100"

TOKYO, Sept 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has joined "RE100", the global environmental initiative that aims to shift the electricity used in business activities to 100% renewable electricity.

RE100 is an initiative committed to shifting the electricity used in business activities to 100% renewable energy with the aim of realizing a carbon-free society, and about 300 companies have joined worldwide. The Climate Group, an international environmental NGO, operates RE100 in partnership with CDP.

In May 2021, Eisai declared that it would achieve carbon neutrality in 2040 as a long-term goal for greenhouse gas (GHG) reduction. In addition, Eisai aims to increase the renewable energy usage rate of electricity throughout the Eisai Group to 100% by 2030 as its medium-term goal. With the accession to RE100, Eisai will accelerate its efforts to achieve the goals, promoting the use of solar power generation based on the PPA (Power Purchase Agreement) model and installing power generation equipment using natural energy in addition to the promotion of energy conservation and renewable energy utilization that has been carried out in Eisai. 

Regarding Eisai's accession to RE100, Sam Kimmins, Head of RE100 at Climate Group said: "We are delighted that Eisai has joined RE100 the global initiative led by the Climate Group in partnership with CDP. By committing to 100% renewable electricity by 2030, Eisai is taking leadership in climate action. They join more than 50 Japanese RE100 companies who collectively, send a powerful message that renewable electricity makes good business sense."

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides, and Eisai calls this philosophy the "human health care (hhc)" philosophy, in one word. To realize this hhc philosophy, Eisai will further strengthen its activities to ensure the sustainability of the global environment, which is the basis of its business activities.

For more detailed information about Eisai's environmental activities, please visit
https://www.eisai.com/sustainability/environment/index.html

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: Environment, ESG, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: